Table 2.

Univariate and multivariate analysis of prognostic factors and pretreatment DBP expressions at diagnosis in EOC (n = 115)

Univariate analysis variableDeath eventsMedian time to death (months)HR for death (95% CI)PProgression eventsMedian time to progression (months)HR for progression (95% CI)P
Ascitic DBPHigh29452.36 (1.11–4.99)0.02540203.08 (1.57–6.04)0.001
Low91.00111.00
Serum DBPHigh18450.71 (0.37–1.38)0.31524360.88 (0.50–1.54)0.650
Low181.0025491.00
Serum CA125High20541.76 (0.88–3.49)0.10830182.58 (1.38–4.81)0.003
Low141.00151.00
Age (years)≥ 53181.06 (0.56–2.02)0.85727271.25 (0.72–2.18)0.429
< 53201.0024491.00
BMI≥ 2318541.15 (0.61–2.18)0.66123491.08 (0.62–1.87)0.798
< 23201.0028331.00
FIGO stageAdvanced32404.30 (1.78–10.35)0.00141173.48 (1.73–6.99)<0.001
Early61.00101.00
HistologySerous25402.19 (1.11–4.31)0.02434192.38 (1.32–4.28)0.004
Non-serous131.00171.00
Residual tumor nodule diameter≥ 1 cm16303.56 (1.82–6.98)<0.00118132.43 (1.35–4.37)0.003
<1 cm221.00331.00
Multivariate analysis variableHR (95% CI) for deathPHR (95% CI) for progressionP
Ascitic DBP level (high vs. low)1.96 (0.83–4.64)0.1252.85 (1.35-6.01)0.006
Serum CA125 level (high vs. low)0.99 (0.47–2.01)0.9671.63 (0.83-3.23)0.157
FIGO stage (advanced vs. early)2.80 (1.08–7.25)0.0342.64 (1.29-5.41)0.008
Histology (serous vs. nonserous)0.67 (0.28–1.60)0.3650.90 (0.42–1.96)0.793
Residual tumor diameter (≥1 vs. <1 cm)2.80 (1.30–6.03)0.0091.35 (0.68-2.67)0.395
  • NOTE: Data were analyzed by Cox proportional hazard regression model. Ascitic DBP levels were categorized as >140.7 μg/mL (high) and ≤140.7 μg/mL (low); serum DBP levels as >280.1 μg/mL (high) and ≤280.1 μg/mL (low); serum CA125 level as >512.1 U/mL (high) and ≤512.1 U/mL (low). Multivariate analysis model was adjusted for ascitic DBP, CA125, stage, histology, and residual tumor diameter.

  • Abbreviations: BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics.